Skip to main navigation menu Skip to main content Skip to site footer

Review article: Biomedical intelligence

Vol. 142 No. 3132 (2012)

Infections in paediatrics: old and new diseases

  • Klara M Posfay-Barbe
DOI
https://doi.org/10.4414/smw.2012.13654
Cite this as:
Swiss Med Wkly. 2012;142:w13654
Published
29.07.2012

Abstract

Paediatric infectious diseases have been reported since Hippocrates, and were always closely linked with the evolution of medicine. Current insights and recommendations by the Pediatric Infectious Diseases Group of Switzerland for the management of common paediatric diseases, such as acute otitis media, pharyngitis, and acute viral gastroenteritis are reviewed. The emergence of “old” vaccine-preventable diseases – pertussis and measles – is also discussed. Furthermore, the impact of the appearance of new hosts in paediatric – very low birthweight infants, immunosuppressed patients – is evaluated. Finally, new emerging paediatric infectious diseases caused by newly discovered viruses, such as human metapneumovirus, human bocavirus, or human coronavirus NL63 are explored. This overview gives a general idea on some topics that are currently significant and specific to paediatric infectious diseases.

References

  1. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379(9832):2151–61.
  2. Still GF. The history of paediatrics. London: Oxford University Press; 1931.
  3. Colón A, Colón P. Nurturing children, a history of pediatrics. Press G (editor). Westport; 1999.
  4. Paradise JL, Rockette HE, Colborn DK, Bernard BS, Smith CG, Kurs-Lasky M, et al. Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics. 1997;99(3):318–33.
  5. DiFranza JR, Lew RA. Morbidity and mortality in children associated with the use of tobacco products by other people. Pediatrics. 1996;97(4):560–8.
  6. Chonmaitree T. Viral and bacterial interaction in acute otitis media. Pediatr Infect Dis J. 2000;19(5 Suppl):S24–30.
  7. Jacobs MR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrob Agents Chemother. 1998;42(3):589–95.
  8. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187–95.
  9. Jansen AG, Hak E, Veenhoven RH, Damoiseaux RA, Schilder AG, Sanders EA. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev. 2009(2):CD001480.
  10. Stamboulidis K, Chatzaki D, Poulakou G, Ioannidou S, Lebessi E, Katsarolis I, et al. The impact of the heptavalent pneumococcal conjugate vaccine on the epidemiology of acute otitis media complicated by otorrhea. Pediatr Infect Dis J. 2011;30(7):551–5.
  11. Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398–412.
  12. OFSP. [Maladies à pneumocoques]. Bull OFSP. 2010;47:1121–7.
  13. Shaikh N, Leonard E, Martin JM. Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis. Pediatrics. 2010;126(3):e557–64.
  14. Randolph MF, Gerber MA, DeMeo KK, Wright L. Effect of antibiotic therapy on the clinical course of streptococcal pharyngitis. J Pediatr. 1985;106(6):870–5.
  15. Needham CA, McPherson KA, Webb KH. Streptococcal pharyngitis: impact of a high-sensitivity antigen test on physician outcome. J Clin Microbiol. 1998;36(12):3468–73.
  16. Pickering LK, Baker CJ, Kimberlin DW, Long SS. Group A streptococcal infections. In: Pediatrics AAP, editor. Red Book: 2009 Report of the Committee on Infectious Diseases 28th ed. Elk Grove Village, IL; 2009. p. 616–28.
  17. Chiappini E, Regoli M, Bonsignori F, Sollai S, Parretti A, Galli L, et al. Analysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and children. Clin Ther. 2011;33(1):48–58.
  18. Centor RM, Allison JJ, Cohen SJ. Pharyngitis management: defining the controversy. J Gen Intern Med. 2007;22(1):127–30.
  19. Kaplan EL, Johnson DR, Del Rosario MC, Horn DL. Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997. Pediatr Infect Dis J. 1999;18(12):1069–72.
  20. Pandey M, Batzloff MR, Good MF. Vaccination against rheumatic heart disease: a review of current research strategies and challenges. Curr Infect Dis Rep. 2012;14(4):381–90.
  21. Sullivan P, Woodward WE, Pickering LK, DuPont HL. Longitudinal study of occurrence of diarrheal disease in day care centers. Am J Public Health. 1984;74(9):987–91.
  22. Duggan C, Lasche J, McCarty M, Mitchell K, Dershewitz R, Lerman SJ, et al. Oral rehydration solution for acute diarrhea prevents subsequent unscheduled follow-up visits. Pediatrics. 1999;104(3):e29.
  23. Tamer AM, Friedman LB, Maxwell SR, Cynamon HA, Perez HN, Cleveland WW. Oral rehydration of infants in a large urban U.S. medical center. J Pediatr. 1985;107(1):14–9.
  24. Prevention CfDC. Withdrawal of Rotavirus Vaccine Recommendation. MMWR. 1999;48(43).
  25. OFSP. Vaccination contre les rotavirus: pas d’introduction dans le Plan suisse de vaccination. Bull OFSP. 2008;28:492–5.
  26. Mastrantonio P, Stefanelli P, Giuliano M, Herrera Rojas Y, Ciofi degli Atti M, Anemona A, et al. Bordetella parapertussis infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates. J Clin Microbiol. 1998;36(4):999–1002.
  27. World Health Organization (WHO). Pertussis vaccine: WHO position paper. Weekly Epidemiological Record. 2010;40(85):6.
  28. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA. 1995;273(13):1044–6.
  29. Wendelboe AM, Hudgens MG, Poole C, Van Rie A. Estimating the role of casual contact from the community in transmission of Bordetella pertussis to young infants. Emerg Themes Epidemiol. 2007;4:15.
  30. Pickering LK, Baker CJ, Kimberlin DW, Long SS. Pertussis (Whooping Cough). In: Pediatrics AAP, editor. Red Book: 2009 report of the Committee on Infectious Diseases 28th ed. Elk Grove Village, IL; 2009;504–20.
  31. OFSP. Optimisation des rappels vaccinaux contre la diphtérie, le tétanos et la coqueluche (dT/dTpa) chez l’adulte. Bull OFSP. 2011;51:1161–71.
  32. OFSP. Coqueluche/Pertussis. Journal [serial on the Internet]. 2012 last accessed July 11, 2012: Available from: http://www.bag.admin.ch/themen/medizin/00682/00684/01082/index.html?lang=fr.
  33. Halperin SA, Bortolussi R, MacLean D, Chisholm N. Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr. 1989;115(5 Pt 1):686–93.
  34. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007;26(4):293–9.
  35. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005 ;353(15):1555–63.
  36. Halperin SA, Sweet L, Baxendale D, Neatby A, Rykers P, Smith B, et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? Pediatr Infect Dis J. 2006;25(3):195–200.
  37. OFSP. L’épidémie de rougeole se poursuit en Suisse. Bull OFSP. 2008;24:430–2.
  38. OFSP. Nouvelle vague de l’épidémie de rougeole en début d’année 2009: description et mesures. Bull OFSP. 2009;27:484–91.
  39. Peltola H, Heinonen OP, Valle M, Paunio M, Virtanen M, Karanko V, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med. 1994;331(21):1397–402.
  40. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol. 2007;7(5):379–90.
  41. Bajwa NM, Berner M, Worley S, Pfister RE. Population based age stratified morbidities of premature infants in Switzerland. Swiss Med Wkly. 2011;141:w13212.
  42. Bizzarro MJ, Raskind C, Baltimore RS, Gallagher PG. Seventy-five years of neonatal sepsis at Yale: 1928-2003. Pediatrics. 2005;116(3):595–602.
  43. Stoll BJ, Hansen N. Infections in VLBW infants: studies from the NICHD Neonatal Research Network. Semin Perinatol. 2003;27(4):293–301.
  44. Neubert A, Lukas K, Leis T, Dormann H, Brune K, Rascher W. Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis. Eur J Clin Pharmacol. 2010;66(1):87–95.
  45. Zingg W, Pfister R, Posfay-Barbe KM, Huttner B, Touveneau S, Pittet D. Secular trends in antibiotic use among neonates: 2001-2008. Pediatr Infect Dis J. 2011;30(5):365–70.
  46. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164(9):552–8.
  47. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–7.
  48. Zingg W, Posfay-Barbe KM. Antibiotic use in children - off-label use. Curr Drug Targets. 2012 Apr 18.
  49. Kwan-Gett TS, Baer A, Duchin JS. Spring 2009 H1N1 influenza outbreak in King County, Washington. Disaster Med Public Health Prep. 2009;3 Suppl 2:S109–16.
  50. Launes C, Garcia-Garcia JJ, Martinez-Planas A, Moraga F, Astigarraga I, Aristegui J, et al. 2009 H1N1: risk factors for hospitalization in a matched case-control study. Eur J Pediatr. 2012;21.
  51. OFSP. [Office Fédéral de la Santé Publique. Grippe saisonnière 2008/2009. Epidémiologie, virologie, approvisionnement en vaccins et composition des vaccins]. Bull OFSP. 2009;2009:523–9.
  52. Baer G, Schaad UB, Heininger U. Clinical findings and unusual epidemiologic characteristics of human metapneumovirus infections in children in the region of Basel, Switzerland. Eur J Pediatr. 2008;167(1):63–9.
  53. van den Hoogen BG, van Doornum GJ, Fockens JC, Cornelissen JJ, Beyer WE, de Groot R, et al. Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients. J Infect Dis. 2003;188(10):1571–7.
  54. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719–24.
  55. Skiadopoulos MH, Biacchesi S, Buchholz UJ, Riggs JM, Surman SR, Amaro-Carambot E, et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol. 2004;78(13):6927–37.
  56. van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, et al. Identification of a new human coronavirus. Nat Med. 2004;10(4):368–73.
  57. Kaiser L, Regamey N, Roiha H, Deffernez C, Frey U. Human coronavirus NL63 associated with lower respiratory tract symptoms in early life. Pediatr Infect Dis J. 2005;24(11):1015–7.
  58. van der Hoek L, Sure K, Ihorst G, Stang A, Pyrc K, Jebbink MF, et al. Croup is associated with the novel coronavirus NL63. PLoS Med. 2005;2(8):e240.
  59. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102(36):12891–6.
  60. Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, Soderlund-Venermo M. Human bocavirus-the first 5 years. Rev Med Virol. 2012;22(1):46–64.
  61. Jartti T, Jartti L, Ruuskanen O, Soderlund-Venermo M. New respiratory viral infections. Curr Opin Pulm Med. 2012;18(3):271–8.
  62. Steinbrook R. Testing medications in children. N Engl J Med. 2002;347(18):1462–70.

Most read articles by the same author(s)